Fig. 3.

TRI-MP treatment yields long-term surviving allografts with reduced expression of inflammatory mediators (PRF1, SRGN, TNF, and IL17A) and increased expression of IFNG and Treg-associated cytokines (IL10, TGFB1, and EBI3 [subunit of IL-35 heterodimer]). Relative mRNA expression in skin samples from rejecting hindlimb allografts (n = 17–20, POD = 33–45) vs. surviving TRI-MP–treated hindlimb allografts (n = 7, POD > 300). Expression levels are presented as fold changes (2^-ΔΔCt) relative to naïve skin (n = 11–13). Bars represent mean ± SD, and dots represent values from individual rats. Significant differences are indicated by *P < 0.05, **P < 0.01, or ***P < 0.001.